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vious infections (eg, tuberculosis, histoplasmosis, diph-
theria), to inhalation burns, or to uncertain causes. 
The treatment of choice for such lesions is tracheal
resection and reconstruction. Surgery, however, is not
always possible both for local reasons (extensive longi-
tudinal damage, excessive subglottic involvement, aspi-
ration pneumonia due to laryngeal dysfunction)1 and
for general contraindications; age and associated med-
ical diseases rarely contraindicate the operation, which
usually is carried out through a neck incision.
Nevertheless, some patients cannot be considered surgi-
cal candidates from the outset because of poor general
condition or because they are uncooperative as a result
of concomitant neurologic problems related to the orig-
C icatricial tracheal stenoses are mainly related toiatrogenic injury (postintubation, post-tracheotomy,
or postoperative). Less common lesions are due to pre-
Objective: Tracheal stenting for cicatricial stenoses is reserved for patients
whose lesions are deemed inoperable for local or general reasons. The aim
of our study was to verify the long-term results of silicone tracheal stents in
such a clinical setting.
Methods: Clinical data of 45 patients treated by tracheal silicone stents,
between 1987 and 1999, were reviewed. All patients had highly symptomatic
cicatricial stenoses; they were selected for stenting rather than for surgery
because of local and general conditions. This series has been divided in two
groups according to the purpose of stenting: bridge to surgery or definitive
treatment. Follow-up ranged between 12 and 83 months. Twenty-seven
patients received a Montgomery T tube (Hood Laboratories, Pembroke,
Mass), 16 a Dumon stent (Novatech, Plan de Gras, France), and 2 a Dynamic
stent (Rusch, Kernen, Germany).
Results: No procedure-related mortality was observed. Nine patients underwent
curative resection and reconstruction after a variable stenting period; one had a
recurrent stenosis and was treated for palliation with a T tube. Tracheal stenting
was performed for palliation as a definitive treatment in 37 patients. Among this
group, 11 patients died of unrelated causes at a median of 10 months after the
endoscopic treatment. The stent was permanently removed in 10 after a medi-
an interval of 32 months (range 9-70 months); in 4 others, symptomatic recur-
rence of the stenosis was observed within 6 weeks of stent removal. None of the
patients successfully decannulated had a completely normal tracheal lumen but
all remained asymptomatic because the residual stenosis was mild or well tol-
erated for concomitant limitation of physical activity.
Conclusions: Long-term treatment with a silicone stent was safe and well tol-
erated in cicatricial tracheal stenoses. This procedure can be considered as a
bridge to curative surgery or as a definitive treatment. The latter, generally
performed for palliation, may provide satisfactory therapeutic results in
selected patients, even in the presence of severe circumferential stenoses.  
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Dumon stent migration. Y-shaped stents (Dynamic) were
reserved for palliation of lesions of the lower third of the tra-
chea; in all the remaining patients we preferred the use of a
Dumon stent. Airway stents were positioned through a venti-
lating rigid bronchoscope with the patient under general
anesthesia. Before stent deployment an adequate tracheal
lumen was restored (bougienage, balloon dilatation, rigid
bronchoscopes of increasing diameter). In the patients eligi-
ble for Montgomery T tube stenting, the tracheostomy—if
not already present—was performed in the diseased segment
of the airway with the aid or a rigid bronchoscope. 
Bronchial secretions for bacteriology were collected in all
patients every 4 months by a flexible bronchoscope. In case
of positive cultures, therapy was instituted according to spe-
cific antimicrobial sensitivity.
All patients underwent large-drop aerosol treatment. T tubes
were replaced with larger bore T tubes every 12 to 15 months
whenever possible. All patients submitted to stent removal
underwent periodic clinical and endoscopic examinations for at
least 1 year. During this period flexible video-endoscopy with
recording was performed roughly every 3 months. After T-tube
removal a stoma stent was positioned. The tracheostomy stoma
was closed after an observation period of about 2 months. 
To analyze the long-term outcome, we divided the patients
according to the initial aim of the treatment: group A under-
went stenting as a bridge to surgery and group B, stenting as
a definitive treatment.
Results
Twenty-eight stenoses were classified as postintuba-
tion, 16 as post-tracheostomy, and 2 as postoperative (1
of which was a recurrent stenosis in a patient who had
previously undergone stenting). Table I summarizes the
endoscopic data collected at the first examination with
a rigid bronchoscope. 
Patients were selected for stenting at the time of pre-
sentation after an accurate appraisal of the local situa-
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inal cause of the prolonged intubation. In a few of these
patients, temporary tracheal stenting allows a subse-
quent, safer, curative resection; surgery can thus be per-
formed after weaning off the patient from steroids,
improvement of clinical status, and resolution of local
inflammation.2,3 Therapeutic options for the remaining
patients are dilatation, laser therapy, and stenting. With
very few exceptions, the effects of dilatation and laser
are of short duration and repeated treatments are
required.4,5 On the other hand, airway stenting can be
considered a valid therapeutic measure for long-lasting
palliation. Occasionally, prolonged splinting achieves
successful tracheal stabilization and thus allows defini-
tive removal of the stent.3,6,7 Long-term stenting might
therefore yield good therapeutic results, but indications
and technical details remain undetermined because few
clinical data are available.
The objective of this report is to present our experi-
ence in the treatment of cicatricial tracheal stenoses by
means of different silicone stents, with special empha-
sis on long-term results. 
Patients and methods
In the period 1987 to 1999, 71 patients with highly symp-
tomatic cicatricial tracheal stenoses were observed. Forty-
five, including a case of postoperative recurrent stenosis,
underwent airway stenting. The remaining 26, treated by
immediate successful tracheal resection and reconstruction,
will not be considered in this study. Patients with a follow-up
shorter than 12 months were not included in this series.
Twenty-eight patients were male and 17 female with ages
ranging from 8 to 79 years (median 58 years). 
Patients were selected for stenting as first treatment rather
than for tracheal resection and reconstruction according to
local and general conditions. Temporary or definitive local
contraindications for surgery included the following: florid
inflammation at the site of the stenosis, excessive linear
extent of the lesion (roughly 50% or more of the tracheal
length), involvement of the proximal half of the subglottic
larynx, and incompetent glottis with previous aspiration
pneumonia. General conditions were usually related to the
disease that caused a prolonged intubation, such as respirato-
ry failure, sequelae of head injury, or neurosurgical proce-
dures (impairment of mental function, post-traumatic epilep-
sy, quadriplegia); these problems were particularly frequent
in our series since most of our patients were referred from
intensive care units. High-dose steroid therapy was also con-
sidered a contraindication for immediate resection.
Long-term stenting was achieved by 3 different silicone
prostheses: Montgomery T tube (Hood Laboratories,
Pembroke, Mass), Dumon stent (Novatech, Plan de Gras,
France), and Dynamic stent (Rusch, Kernen, Germany). We
used T tubes in very long stenoses (>5 cm), in the presence of
an already existing tracheostomy stoma, in uncooperative
patients with ineffective cough, and in patients with previous
Table I. Endoscopic data
No.
Site of the lesion
Upper trachea 22
Subglottic larynx–upper trachea 10
Lower trachea 13
Longitudinal extent
<3 cm 26
3-5 cm 15
>5 cm 4
Stenosis*
Mild 4
Moderate 20
Severe 21
Associated malacia 18
*Mild, Residual lumen > 50%; moderate, residual lumen 30% to 50%; severe,
residual lumen < 30%.
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tion, as evaluated with a rigid bronchoscope, and the
clinical conditions. Six patients were deemed to have
an unresectable lesion as a result of extensive destruc-
tion of the proximal half of the subglottic larynx and 4
as a result of involvement of more than half of the tra-
chea. Three patients in this particular subgroup had
previously undergone repeated laser treatments else-
where. Four patients had significant laryngeal dysfunc-
tion related to a recent supraglottic partial laryngecto-
my. The remaining 31 patients had a potentially
resectable lesion. In 7 of these, a tracheal stent was
positioned because of florid tracheal inflammation. At
the first observation, 24 patients were unsuitable for
surgery because of their general clinical conditions: on
referral, 6 were intubated and receiving mechanical
ventilation with the endotracheal tube positioned above
the stricture; 5 were comatose or had severe neurolog-
ic sequelae; 10 were affected by chronic obstructive
pulmonary disease and had undergone repeated intuba-
tions with mechanical ventilation for recurrent
episodes of respiratory failure; and 3 had required pro-
longed intubation as a result of a recent myocardial
infarction.
Long-term stenting was achieved by a Montgomery
T tube in 27 patients, a Dumon stent in 16, and a
Dynamic stent in 2.
There has been no hospital mortality. All patients had
immediate symptomatic relief after the endoscopic
treatment; the mechanically ventilated patients were
immediately extubated.
The median follow-up period was 36 months (12-83
months).
Complications 
Migration. Three Dumon stents (18.7%) became dis-
placed in this series. This complication was solved by
changing diameter or stent type. 
Mucostasis. Only 3 emergency bronchial aspirations
were required. Mildly symptomatic mucostasis was
also observed in 14 patients. This complication
occurred with all stent types and was easily solved by
fiberoptic bronchial aspiration and by improving the
mucolytic medication.
Granulation tissue. Asymptomatic granulomas at the
edges of the stent were not considered complications.
Significant granulomas inducing stenosis were
observed at the proximal end of the T tube when it
reached a level immediately below the glottis. This
complication was managed by proper size selection
and accurate smoothing of the stent’s edges. We always
avoided placing the proximal arm of the T tube above
the level of the vocal cords because of the risk of aspi-
ration. In 1 case of extensive subglottic destruction, a
temporary Eliachar laryngeal stent (Hood Laboratories,
Pembroke, Mass) was positioned.
Infection. Symptomatic airway infection by Candida
albicans and by Pseudomonas aeruginosa occurred in 2
patients and was successfully managed by antibiotic ther-
apy and stent replacement (Dumon stent and T tube).
Other complications. In 2 patients who underwent
tracheostomy and immediate T-tube placement, the
stent was kept unplugged for 5 or 6 days because of
subcutaneous emphysema. 
The long-term outcome of the two groups of patients,
as previously divided, was as follows:
Group A: Stenting as a bridge to surgery. Tracheal
stenting prepared 9 patients for a curative tracheal or
laryngotracheal resection and reconstruction. The
median interval between stent deployment and surgery
Table II. Clinical data of the patients successfully decannulated after stenting
Residual Residual 
Patient Longitudinal Degree Stenting stenosis* malacia 
(sex, age extent Associated of period after after
[y]) Etiology Site of the lesion (cm) malacia stenosis* Stent (mo) decannulation decannulation
1 (F, 50) Postintubation Upper-middle trachea 4 Yes Severe T tube 60 Mild Yes
2 (F, 73) Postintubation Larynx-upper trachea 4 Yes Severe T tube 32 Mild Yes
3 (M, 69) Post-tracheostomy Upper trachea 2 No Severe Dumon 9 Moderate No
4 (M, 39) Postoperative Upper trachea 2 No Severe T tube 50 Mild No
5 (M, 30) Postintubation Larynx-upper trachea 3 Yes Severe Dumon 70 Moderate Yes
6 (M, 70) Post-tracheostomy Upper-middle trachea 6 No Severe T tube 48 Moderate No
7 (F, 51) Postintubation Upper trachea 4 Yes Moderate T tube 40 Mild No
8 (M, 64) Postintubation Upper trachea 3 No Severe Dumon 23 Moderate No
9 (M, 66) Postintubation Upper trachea 4 Yes Moderate T tube 12 Mild Yes
10 (F, 54) Postintubation Larynx-upper trachea 2 Yes Moderate T tube 19 Mild No
*Mild, Residual lumen > 50%; moderate, residual lumen 30% to 50%; severe, residual lumen < 30%.
was 9 months, ranging from 4 to 67 months. As soon as
the stent was removed an antibiotic regimen was insti-
tuted; after a median of 3 days the patients were re-
evaluated with a rigid bronchoscope and operated on
with a curative intent. The postoperative course was
uneventful in all patients but 1 who received a new
stent (T tube) for recurrent tracheal stenosis due to
anastomotic separation (this case is also included in
group B).
Group B: Stenting as a definitive treatment.
Tracheal stenting was considered the only valid alter-
native to tracheostomy in 37 patients who were deemed
to be in inoperable condition because of local or gener-
al reasons, or both. All patients were initially treated
with a silicone stent for palliation. 
Four patients in this group were lost to follow-up; 11
died of the concomitant diseases without respiratory
symptoms at a median of 10 months after stent place-
ment. The stent is still in place in 12 patients, all
asymptomatic. 
In 14 patients we attempted decannulation after long-
term splinting. Symptomatic recurrence of the stenosis
was observed in 4 patients, within 6 weeks of stent
removal, and a new stent was positioned. The stent was
thus permanently removed in 10 patients after a medi-
an interval of 32 months (range 8-70 months). Clinical
data of the patients successfully decannulated after
long-term stenting are reported in Table II. Two
patients in this subgroup had undergone a previously
unsuccessful attempt at stent removal 14 and 23
months earlier. In all patients the bronchoscopic exam-
ination after stent removal showed acceptable regres-
sion of the stenosis, sometimes with scattered granulo-
mas but always with satisfactory epithelialization;
residual tracheal malacia was observed in 4 cases. No
patient had a totally normal tracheal lumen at follow-up
examination with a fiberoptic scope. However, the
residual stricture was well tolerated because of its lim-
ited entity (6 patients) or the patient’s restricted physi-
cal activity (4 patients). A comparative analysis of the
sequential endoscopic recordings showed further mild
asymptomatic narrowing of the tracheal lumen in 50%
of patients, occurring within 40 days after stent
removal. In 2 patients we observed resorption of the
residual granulomas discovered at the edge of the pros-
thesis. One patient died 34 months after stent removal
of unrelated causes.
Discussion
Despite widespread use of low-pressure/high-volume
cuffs, postintubation trauma is still the main cause of
benign tracheal stricture. These lesions have been
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attributed to impairment of blood flow caused by
mucosal or full-thickness tracheal pressure necrosis
due to the cuff.8 Furthermore, other causes, as well as
some kind of individual predisposition, are to be postu-
lated since this problem may occur after a wide vari-
ability of traumas. The deeper the tissue injury, the
tighter the ensuing stenosis; thinning or destruction of
the cartilages will lead to a circumferential stricture
and associated malacia.
Laryngotracheal stenoses may be related to trauma
from intubation with a tube that is too large, causing
mucosal tear at the cricoid level, generally the narrow-
est segment of the upper airway, especially in female
patients.
Post-tracheostomy stenoses are usually caused by
poor surgical technique. A stoma that is too large, with
excessive destruction of the anterior cartilaginous arch,
may produce a generally resectable triangular stenosis.
Much more difficult to correct are lesions of the sub-
glottic larynx, caused by incorrect position of the stoma
for technical or anatomic reasons (short neck, severe
kyphosis).
Most postoperative stenoses are caused by excessive
tension on the anastomosis or, less frequently, by other
technical defects (eg, inadequate blood supply, florid
inflammation of the tracheal stumps). Secondary resec-
tion, even though sometimes feasible,9 can be extreme-
ly difficult.
In cicatricial tracheal stenoses, 3 different clinical
patterns may be described.
Well-circumscribed lesion: Patient with good per-
formance status. In this group early resection must be
considered. Dilatation with bougies, balloons, and rigid
bronchoscopes can be indicated to allow elective
surgery with safer intraoperative control of the airway
and to measure the lesion and its distance from the
vocal cords, cricoid, and carina, as we10 previously
reported. Repeated endoscopic treatments are con-
traindicated because the effect of dilatation does not
last very long.4,5 Laser treatment is effective only for
isolated inflammatory granulomas or thin weblike
stenoses,11 and its indiscriminate use can jeopardize the
subsequent curative surgical resection.5,8,12 Stent inser-
tion is to be avoided because it delays the curative treat-
ment.
Florid inflammation and excessive scar tissue are
discovered all around the stricture or the patient
requires rehabilitation. In such circumstances, tem-
porary tracheal stenting with a silicone stent is a suit-
able treatment until the local situation and the patient’s
general condition allow a safer surgical resection. In
fact, it is wiser to gain time in order to permit resolu-
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tion of active inflammation of the operative field and to
obtain a significant improvement of the clinical status.
Six months are usually enough for the first purpose.
With silicone stents it is possible to provide a stable
respiratory lumen without repeated procedures, avoid-
ing an open tracheostomy stoma.3,13
More than 50% of the trachea is damaged, the
subglottic larynx is entirely involved, or the patient
has post-traumatic irreversible sequelae or associat-
ed disabling diseases. Surgical correction, whenever
feasible, is risky and technically very difficult. Most of
the patients have unresectable lesions, and a tracheal
stent can be the only reliable alternative to a tra-
cheostomy cannula.
We believe that the combination of tracheal resection
and reconstruction is the best treatment for most cica-
tricial stenoses. The aim of this study is not to demon-
strate that long-term stenting may be an alternative to
surgery. Roughly 50% of the patients in our series did
not undergo surgery—either immediate or delayed—
because most of them were referred from intensive care
units with associated severe medical problems. In
uncooperative patients with resectable tracheal
stenoses but with mental deterioration, and/or severe
limitation of physical activity, and/or ineffective cough,
silicone stenting may be considered a good therapeutic
measure. Even though in our institution tracheal stent-
ing was always used for palliation, surprisingly we
found that stent removal was possible, in the long term,
in some severe circumferential stenoses with associat-
ed malacia. 
Many questions concerning long-term silicone stent-
ing as potentially curative are still matters of debate.
Are all cicatricial tracheal stenoses amenable to
cure by long-term stenting? The answer is probably
no, but certainly all these lesions do have a chance of
significant improvement after prolonged stenting. The
use of silicone stents with curative intent has been
reported, probably on the basis of endoscopic criteria.6
Such criteria are related to the depth of damage:
Superficial tracheal injury, involving only the mucosa
with granuloma formation, is more likely to improve
after splinting with a highly tolerated material; perma-
nent recovery of full-thickness lesions with total
destruction of tracheal cartilages is of course much
more difficult to achieve. In our series none of the
patients with severe lesions had a totally normal tra-
cheal lumen after stent removal.
Which stent is preferable? Metallic stents should be
avoided in benign lesions because they are often very
difficult to remove and can produce severe tracheal wall
damage after a prolonged stenting period.11,14,15
Furthermore, the inflammatory stricture often recurs by
ingrowth through the wire mesh.16 Experimentally, we17
recently observed full-thickness bronchial perforations
after long-term metallic stenting; after the same period
of silicone stenting, only chronic reversible inflamma-
tory changes were discovered. The choice of the appro-
priate silicone stent depends on several factors: topog-
raphy and extension of the lesion, the patient’s general
condition, and pre-existing tracheostomy. We prefer to
use the T tube in high, extended tracheal or laryngotra-
cheal strictures, in patients with repeated migration of a
Dumon stent, in uncooperative patients with severe neu-
rologic problems, and in patients in whom it is safer to
keep the tracheostomy open (ie, patients likely requiring
mechanical ventilation or repeated general anesthesia
for the treatment of associated diseases). T tubes of
gradually increasing sizes are used whenever possible to
obtain optimal airway splinting. Lesions of the lower
third of the trachea are best treated by bifurcated pros-
theses (Dynamic stent, Dumon type, Hood stent). In
nearly all the other situations we consider the Dumon
stent as a first choice because it avoids a tracheostomy
or allows the closure of a pre-existing stoma. Dumon
stent migration rate can be kept quite low by choosing
the proper stent diameter. The largest size accepted by
the airway is indicated because the prosthesis probably
will not have to be replaced (only 1 patient in our series
required replacement of the prosthesis, for symptomatic
Candida infection). In benign stenoses a certain
Dumon stent migration rate should be expected18
because the diameter of the diseased trachea gradually
increases as a result of the dilatation pressure of the
stent.
How long should the stent be kept in place before
attempting its removal? Some authors recommend
keeping the stent in place for at least 6 to 123,19 or 18
months.6 Probably the optimal period of stenting is
related to the severity of the lesion. In full-thickness
damage, the diseased trachea can be converted into a
floppy tube, and stabilization, whenever possible, usu-
ally takes some years to occur. Resolution of stenosis
and stabilization of malacia are seldom entirely
achievable, but in the long term it is possible to obtain
an adequate airway lumen, especially for those
patients with limited physical activity due to the trau-
ma-related neurologic sequelae. We believe that at
least 2 years are necessary before attempting stent
removal in severe circumferential stenoses with asso-
ciated tracheal malacia. In some patients an even
longer time may be necessary. 
How do such lesions undergo stabilization?
Localized granulomas can be cured either by laser or
The Journal of Thoracic and
Cardiovascular Surgery
Volume 120, Number 6
Puma et al 1069
by mechanical removal.11,20 Diffuse circumferential
granulation tissue and fibrous scar tissue are usually
the result of extensive mucosal necrosis. A satisfacto-
ry mucosal healing process requires complete re-
epithelialization. Stabilization of malacia is certainly
much more difficult to understand, especially if the
tracheal rings are totally destroyed. As already men-
tioned, a completely stable and patent airway is
impossible to obtain in such circumstances. On the
other hand, with long-term silicone stenting an
unpredictable improvement leading to stent removal
is sometimes observed. The foreign body, chronical-
ly contaminated by bacteria, may play a role in this
process, causing perivisceral adhesions. In conclu-
sion, long-term stenting can produce resolution of
active inflammatory mucosal changes, which gradu-
ally evolve into a full-thickness chronic infiltrate; the
latter may be reversible after stent removal with
fibrous healing.17
Which are the criteria for attempting stent
removal? Clinical and endoscopic criteria are to be
considered. Among the former, the elapsed time is very
important because only long-term stenting may provide
a stable and patent airway. Performance status should
also be considered because a residual tracheal stricture
may be well tolerated by patients unable to carry out
normal daily activity. 
The correct interpretation of endoscopic data is the
key to satisfactory results. Epithelialization, airway
diameter, and residual chondromalacia should be care-
fully evaluated. It is better to remove the T tube under
sedation and local anesthesia to allow subsequent
examination with a fiberoptic bronchoscope, which is
essential for evaluating residual malacia.
The degree of residual stenosis cannot be a reliable
criterion, since the stricture, dilated by long-term
splinting, may not be fully appreciated immediately
after decannulation. Satisfactory patency at this stage
should not be considered definitive owing to the pos-
sibility of subsequent gradual luminal narrowing. For
this reason it is extremely important to schedule a
strict follow-up program, based on sequential video-
recorded endoscopies, to monitor the condition of the
airway. As soon as signs and symptoms of airway
obstruction recur, the patient should receive a new
stent positioned with a rigid bronchoscope. A failed
decannulation after long-term stenting does not nec-
essarily mean that the lesion will not be amenable to
cure after prolonged splinting. In 2 patients in our
series, a stable airway lumen was achieved 14 and 23
months after a first unsuccessful attempt at stent
removal.
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